Last reviewed · How we verify
Nivolumab Extended
At a glance
| Generic name | Nivolumab Extended |
|---|---|
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pericardial Effusion - Grade 0
- Hyperthyroidism - Grade 0
- Hypothyroidism - Grade 0
- Blurred vision - Grade 0
- Decreased vision - grade 0
- Abdominal bloating - Grade 0
- Abdominal distension - Grade 0
- Colitis - Grade 0
- Constipation - Grade 0
- Diarrhea - Grade 0
- Dry Mouth - Grade 0
- Dysphagia - Grade 0
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) (PHASE3)
- A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE2)
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (PHASE2)
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (PHASE1, PHASE2)
- Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer (PHASE2)
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (PHASE2)
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab Extended CI brief — competitive landscape report
- Nivolumab Extended updates RSS · CI watch RSS
- University of Chicago portfolio CI